<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04035785</url>
  </required_header>
  <id_info>
    <org_study_id>Kangfu</org_study_id>
    <nct_id>NCT04035785</nct_id>
  </id_info>
  <brief_title>A Clinical Study on Kangfu Anti-inflammatory Suppository of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Evidence of Dampness and Heat Accumulation)</brief_title>
  <official_title>A Clinical Study on Kangfu Anti-inflammatory Suppository of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Evidence of Dampness and Heat Accumulation):a Randomized, Double Blind, Parallel Control of Positive Drugs,Multi-center Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiyuan Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Obstetrics and Gynecology Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Longhua Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Hospital of Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Maternal and Child Health Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Heilongjiang University of Traditional Chinese</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Kangfu Xiaoyan Suppository in the treatment of pelvic&#xD;
      inflammatory diseases (dampness-heat accumulation syndrome) and its influence on the sequelae&#xD;
      of pelvic inflammatory diseases, and to study the role of traditional Chinese medicine in&#xD;
      reducing the use of antibiotics and the risk of clinical medication, taking levofloxacin +&#xD;
      metronidazole as the control drug.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">July 28, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 28, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The MCCormack scale scores of 240 subjects will be assessed</measure>
    <time_frame>Change from base line on the 56 days after discontinuation</time_frame>
    <description>assessment of the 70% reduction rate after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The neutrophils of 240 participants will be assessed</measure>
    <time_frame>Change from base line on the 28 days of medication and 56 days after discontinuation</time_frame>
    <description>assessment of neutrophils returning to normal reference range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The whole blood reduced viscosity from hemorheological tests of 240 participants will be assessed</measure>
    <time_frame>Change from base line on the 28 days of medication and 56 days after discontinuation</time_frame>
    <description>assessment of whole blood viscosity returning to normal reference range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The plasma viscosity from hemorheological tests of 240 participants will be assessed</measure>
    <time_frame>Change from base line on the 28 days of medication and 56 days after discontinuation</time_frame>
    <description>assessment of the plasma viscosity returning to normal reference range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The CRP of 240 participants will be assessed</measure>
    <time_frame>Change from base line on the 28 days of medication and 56 days after discontinuation</time_frame>
    <description>assessment of the CRP returning to normal reference range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The volume of liquid on B-mode of 240 subjects will be assessed</measure>
    <time_frame>Change from base line on the 28 days of medication and 56 days after discontinuation</time_frame>
    <description>The changes of the volume of liquid on B-mode at different observation points before and after treatment will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The white blood cells of 240 participants will be assessed</measure>
    <time_frame>Change from base line on the 28 days of medication and 56 days after discontinuation</time_frame>
    <description>assessment of the white blood returning to normal reference range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The TCM syndrome scores of 240 subjects will be assessed</measure>
    <time_frame>Change from base line on the 56 days after discontinuation</time_frame>
    <description>assessment of the 70% reduction rate after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The VAS score of 240 subjects will be assessed</measure>
    <time_frame>Change from base line on the 56 days after discontinuation</time_frame>
    <description>assessment of the 70% reduction rate after treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Change from base line on the 28 days of medication and 56 days after discontinuation</time_frame>
    <description>Observe the incidence of adverse events after medication</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of liver function</measure>
    <time_frame>Change from base line on the 28 days of medication and 56 days after discontinuation</time_frame>
    <description>To observe whether ALT and AST are within the normal reference range after medication</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of renal function</measure>
    <time_frame>Change from base line on the 28 days of medication and 56 days after discontinuation</time_frame>
    <description>To observe whether creatinine and urea nitrogen are within the normal reference range after treatment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Pelvic Inflammatory Diseases</condition>
  <arm_group>
    <arm_group_label>Kangfu anti-inflammatory suppository</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kangfu Xiaoyan Suppository was used for 21 days, while levofloxacin + metronidazole for 10 days, levofloxacin + metronidazole for 4 days.&#xD;
One of the levofloxacin quinolones has broad-spectrum antimicrobial activity and strong antimicrobial activity.&#xD;
Metronidazole is mainly used to treat or prevent systemic or local infections caused by the above-mentioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antibiotics alone group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One of the levofloxacin quinolones has broad-spectrum antimicrobial activity and strong antimicrobial activity. It has strong antimicrobial activity against most Enterobacteriaceae bacteria, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella and Haemophilus influenzae, Legionella pneumophila, Neisseria gonorrhoeae and other gram-negative bacteria. Bacterial activity.&#xD;
Metronidazole is mainly used to treat or prevent systemic or local infections caused by the above-mentioned anaerobes, such as anaerobic infections in abdominal cavity, digestive tract, female reproductive system, lower respiratory tract, skin and soft tissue, bone and joint, etc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kangfu Anti-inflammatory Suppository</intervention_name>
    <description>To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.</description>
    <arm_group_label>Kangfu anti-inflammatory suppository</arm_group_label>
    <arm_group_label>antibiotics alone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) Women aged 20-50;&#xD;
&#xD;
          -  (2) Sexual History ;&#xD;
&#xD;
          -  (3) According to the diagnostic criteria of pelvic inflammatory diseases: according to&#xD;
             the Diagnosis and Treatment Criteria of Pelvic Inflammatory Diseases (2014), the&#xD;
             following specifications are as follows: A. uterine tenderness, or adnexal tenderness,&#xD;
             or cervical lifting pain; B. axillary body temperature &lt; 38 C. blood routine white&#xD;
             blood cell count &lt; 1.1 times the upper limit of normal value; D. blood routine&#xD;
             neutrophil percentage &lt; 90%;&#xD;
&#xD;
        All of the above four items are available. Exclusion Criteria:&#xD;
&#xD;
          -  (4)McCormack:4-12;&#xD;
&#xD;
          -  (5)TCM syndrome differentiation for damp-heat stagnation and Qi deficiency syndrome,&#xD;
             A. lower abdominal pain; B. excessive amount of belt, yellow color, or odor; C.&#xD;
             fatigue; D. tongue red, greasy fur, or with teeth marks, or blood stasis spots; the&#xD;
             above four items are all available;&#xD;
&#xD;
          -  (6)Those who agree to participate in this clinical trial and sign the informed consent&#xD;
             form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) Pregnant or recent (within 6 months) pregnant women, lactating women ;&#xD;
&#xD;
          -  (2) To identify the pathogen as Neisseria gonorrhoeae;&#xD;
&#xD;
          -  (3) Symptoms related to appendicitis, ectopic pregnancy, torsion or rupture of ovarian&#xD;
             cyst pedicle, gastroenteritis, endometriosis, adenomyosis, trichomonal vaginitis,&#xD;
             vulvovaginal candidiasis, bacterial vaginosis, etc.;&#xD;
&#xD;
          -  (4)Those with critical condition or surgical indications, such as fallopian tube and&#xD;
             ovary abscess, pelvic abscess, diffuse peritonitis, septicemia;&#xD;
&#xD;
          -  (5)In patients with severe primary diseases such as heart, brain and hematopoietic&#xD;
             system, ALT of liver function is higher than the upper limit of normal value, and Cr&#xD;
             of renal function is higher than the upper limit of normal value;&#xD;
&#xD;
          -  (6)One month before admission, Chinese and Western medicines were used to treat the&#xD;
             disease, which made it difficult to judge the efficacy of drugs;&#xD;
&#xD;
          -  (7)Anaphylactic constitution or persons known to be allergic to the medicines and&#xD;
             their components used in this test ;&#xD;
&#xD;
          -  (8)Researchers do not consider it appropriate to participate in this clinical trial;&#xD;
&#xD;
          -  (9)Suspected or true history of alcohol and drug abuse, or other pathological changes&#xD;
             or conditions that reduce the likelihood of enrollment or complicate enrollment, such&#xD;
             as frequent changes in the working environment, unstable living environment, etc., are&#xD;
             liable to lead to lost interviews, according to the judgement of researchers;&#xD;
&#xD;
          -  (10)Participation in other clinical researchers within 3 months before admission;&#xD;
&#xD;
          -  (11)Patients with suspected or confirmed quinolone contraindications, central or&#xD;
             peripheral neuropathy, epilepsy, and depression&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanming Xie</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Basic Research in Clinical Medicine, China Academy of Chinese</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanming Xie, BA</last_name>
    <phone>86-13911112416</phone>
    <email>ktzu2018@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kun Ma, Doctor</last_name>
    <phone>86-13521781839</phone>
    <email>wlxing@126.com</email>
  </overall_contact_backup>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Yanming Xie</investigator_full_name>
    <investigator_title>Deputy director</investigator_title>
  </responsible_party>
  <keyword>Kangfu Anti-inflammatory Suppository</keyword>
  <keyword>efficacy and safety</keyword>
  <keyword>recurrence rate</keyword>
  <keyword>randomized</keyword>
  <keyword>double blind</keyword>
  <keyword>parallel control</keyword>
  <keyword>multi-center clinical study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Inflammatory Disease</mesh_term>
    <mesh_term>Pelvic Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

